vs
ANI PHARMACEUTICALS INC（ANIP）与FTAI Infrastructure Inc.（FIP）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是FTAI Infrastructure Inc.的1.3倍（$247.1M vs $188.4M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -79.7%，领先90.9%），FTAI Infrastructure Inc.同比增速更快（95.9% vs 29.6%），过去两年FTAI Infrastructure Inc.的营收复合增速更高（49.0% vs 34.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
FTAI基础设施有限公司持有、运营并投资交通物流、中游能源、发电等核心领域的优质关键基础设施资产，主要面向北美市场，聚焦拥有稳定长期现金流、合同约定收入流的项目，为利益相关方创造可持续回报。
ANIP vs FIP — 直观对比
营收规模更大
ANIP
是对方的1.3倍
$188.4M
营收增速更快
FIP
高出66.2%
29.6%
净利率更高
ANIP
高出90.9%
-79.7%
两年增速更快
FIP
近两年复合增速
34.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $188.4M |
| 净利润 | $27.5M | $-150.2M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | -79.7% |
| 营收同比 | 29.6% | 95.9% |
| 净利润同比 | 367.5% | -387.6% |
| 每股收益（稀释后） | $1.14 | $-1.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPFIP
| Q1 26 | — | $188.4M | ||
| Q4 25 | $247.1M | $143.5M | ||
| Q3 25 | $227.8M | $140.6M | ||
| Q2 25 | $211.4M | $122.3M | ||
| Q1 25 | $197.1M | $96.2M | ||
| Q4 24 | $190.6M | $80.8M | ||
| Q3 24 | $148.3M | $83.3M | ||
| Q2 24 | $138.0M | $84.9M |
净利润ANIPFIP
| Q1 26 | — | $-150.2M | ||
| Q4 25 | $27.5M | $-97.7M | ||
| Q3 25 | $26.6M | $-104.5M | ||
| Q2 25 | $8.5M | $-70.0M | ||
| Q1 25 | $15.7M | $120.2M | ||
| Q4 24 | $-10.3M | $-124.7M | ||
| Q3 24 | $-24.2M | $-43.0M | ||
| Q2 24 | $-2.3M | $-48.1M |
营业利润率ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | -45.7% | ||
| Q3 25 | 15.9% | -70.8% | ||
| Q2 25 | 6.6% | -56.4% | ||
| Q1 25 | 13.3% | 81.8% | ||
| Q4 24 | -2.3% | -152.7% | ||
| Q3 24 | -13.8% | -51.7% | ||
| Q2 24 | 3.7% | -56.4% |
净利率ANIPFIP
| Q1 26 | — | -79.7% | ||
| Q4 25 | 11.1% | -68.1% | ||
| Q3 25 | 11.7% | -74.4% | ||
| Q2 25 | 4.0% | -57.2% | ||
| Q1 25 | 8.0% | 125.0% | ||
| Q4 24 | -5.4% | -154.4% | ||
| Q3 24 | -16.3% | -51.6% | ||
| Q2 24 | -1.7% | -56.7% |
每股收益（稀释后）ANIPFIP
| Q1 26 | — | $-1.32 | ||
| Q4 25 | $1.14 | $-1.04 | ||
| Q3 25 | $1.13 | $-1.38 | ||
| Q2 25 | $0.36 | $-0.73 | ||
| Q1 25 | $0.69 | $0.89 | ||
| Q4 24 | $-0.45 | $-1.21 | ||
| Q3 24 | $-1.27 | $-0.45 | ||
| Q2 24 | $-0.14 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $37.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $-122.5K |
| 总资产 | $1.4B | $5.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPFIP
| Q1 26 | — | $37.9M | ||
| Q4 25 | $285.6M | $57.4M | ||
| Q3 25 | $262.6M | $34.7M | ||
| Q2 25 | $217.8M | $33.6M | ||
| Q1 25 | $149.8M | $26.3M | ||
| Q4 24 | $144.9M | $27.8M | ||
| Q3 24 | $145.0M | $20.3M | ||
| Q2 24 | $240.1M | $33.1M |
总债务ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | — | $3.8B | ||
| Q3 25 | — | $3.7B | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
股东权益ANIPFIP
| Q1 26 | — | $-122.5K | ||
| Q4 25 | $540.7M | $21.3M | ||
| Q3 25 | $505.8M | $181.1M | ||
| Q2 25 | $436.8M | $375.5M | ||
| Q1 25 | $418.6M | $476.2M | ||
| Q4 24 | $403.7M | $202.7M | ||
| Q3 24 | $405.9M | $370.8M | ||
| Q2 24 | $455.8M | $394.8M |
总资产ANIPFIP
| Q1 26 | — | $5.7B | ||
| Q4 25 | $1.4B | $5.7B | ||
| Q3 25 | $1.4B | $5.5B | ||
| Q2 25 | $1.3B | $4.4B | ||
| Q1 25 | $1.3B | $4.1B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $920.8M | $2.5B |
负债/权益比ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | — | 176.99× | ||
| Q3 25 | — | 20.59× | ||
| Q2 25 | — | 8.21× | ||
| Q1 25 | — | 5.79× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 4.14× | ||
| Q2 24 | — | 3.94× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-69.4M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPFIP
| Q1 26 | — | $-69.4M | ||
| Q4 25 | $30.4M | $-2.8M | ||
| Q3 25 | $44.1M | $-24.4M | ||
| Q2 25 | $75.8M | $-5.2M | ||
| Q1 25 | $35.0M | $-85.7M | ||
| Q4 24 | $15.9M | $-8.1M | ||
| Q3 24 | $12.5M | $14.2M | ||
| Q2 24 | $17.4M | $-17.6M |
自由现金流ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $-68.6M | ||
| Q3 25 | $38.0M | $-90.7M | ||
| Q2 25 | $71.8M | $-87.5M | ||
| Q1 25 | $32.5M | $-151.7M | ||
| Q4 24 | $13.5M | $-34.3M | ||
| Q3 24 | $7.7M | $-11.7M | ||
| Q2 24 | $13.0M | $-32.1M |
自由现金流率ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -47.8% | ||
| Q3 25 | 16.7% | -64.5% | ||
| Q2 25 | 34.0% | -71.6% | ||
| Q1 25 | 16.5% | -157.7% | ||
| Q4 24 | 7.1% | -42.4% | ||
| Q3 24 | 5.2% | -14.0% | ||
| Q2 24 | 9.4% | -37.9% |
资本支出强度ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 45.9% | ||
| Q3 25 | 2.7% | 47.2% | ||
| Q2 25 | 1.9% | 67.3% | ||
| Q1 25 | 1.3% | 68.6% | ||
| Q4 24 | 1.3% | 32.5% | ||
| Q3 24 | 3.2% | 31.1% | ||
| Q2 24 | 3.2% | 17.2% |
现金转化率ANIPFIP
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | -0.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FIP
暂无分部数据
